Topic

Webcasts

Webinar Date/Time: Tuesday, February 14, 2023, 9 am CT, 10 am ET, 3 pm GMT, 4 pm CET

Creating the Future in Clinical Research with CROs Using Real-World Data

 and can be reached at mrivers@mjhlifesciences.com.

Articles

One company pursues a program for a technology they believe is a potential cure for Type 1 diabetes.

Type 1 Diabetes: A Potential Cure

Webinar Date/Time: Tuesday, January 31st 2023 | 9 am CT | 10 am ET | 3 pm GMT | 4 pm CET

The conundrum of proliferating data from decentralized clinical trials

Webinar Date/Time: Tuesday, January 17th, 2023 at 9 am CT, 10 am ET, 3 pm BST, 4 pm CET



How to Accelerate Adoption and Lower TCO With a Configurable RTSM System

Mike Straus is a freelance writer based in British Columbia, Canada. His work has appeared in 

Nutritional Outlook, Hoist, and Massage Therapy Canada

Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.

2023 Pipeline Report: Testing the Limits

Webinar Date/Time: Tuesday, Dec 6, 2022, 11am PT | 2pm ET


Expand Marketing Reach and Enhance Commercial Ops With Real-Time Patient Data

Director of Science Staff, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA

FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.

The Manufacturing Edge on Path to Market

 and can be reached at mhollan@mjhlifesciences.com.

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants 

Launch of novel drug for rare neuromuscular disorder seeks to give voice to the patients.

More Than a Name: Vyvgart

Elaine Quilici is a contributing editor of 

Use against pair of pathways could pave way for standout in stocked eye disease market.

R&D/Clinical Trials